Get the Stockscreener App
12.63
0.96%
0.12
Pre-market:
12.44
-0.19
-1.50%
Astria Therapeutics Inc stock is traded at $12.63, with a volume of 621.52K.
It is up +0.96% in the last 24 hours and up +73.49% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$12.51
Open:
$12.51
24h Volume:
621.52K
Relative Volume:
0.41
Market Cap:
$712.77M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-5.219
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
+1.53%
1M Performance:
+73.49%
6M Performance:
+144.77%
1Y Performance:
+12.97%
1-Day Range:
$12.40
$12.67
1-Week Range:
$12.40
$12.71
52-Week Range:
$3.555
$12.71
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
12.63 | 706.00M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | TD Cowen | Buy |
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
Astria Therapeutics Inc Stock (ATXS) Latest News
Can Astria Therapeutics Inc. stock deliver surprise earnings beatJuly 2025 Market Mood & AI Forecasted Entry/Exit Points - newser.com
What moving averages say about Astria Therapeutics Inc.Trade Volume Report & Smart Allocation Stock Reports - newser.com
Will Astria Therapeutics Inc. stock reach Wall Street targetsQuarterly Earnings Summary & Community Consensus Stock Picks - newser.com
Why Astria Therapeutics Inc. is moving todayStop Loss & Daily Entry Point Trade Alerts - newser.com
Will Astria Therapeutics Inc. stock beat EPS estimatesWeekly Market Report & Comprehensive Market Scan Reports - newser.com
Strategies to average down on Astria Therapeutics Inc.2025 Volume Leaders & Accurate Technical Buy Alerts - newser.com
Intraday pattern recognizer results for Astria Therapeutics Inc.Buy Signal & Technical Pattern Based Signals - newser.com
Why Astria Therapeutics Inc. stock is in analyst buy zone2025 EndofYear Setup & Verified Momentum Stock Alerts - newser.com
Is Astria Therapeutics Inc. stock attractive for income investorsWeekly Market Report & Safe Entry Trade Signal Reports - newser.com
Applying big data sentiment scoring on Astria Therapeutics Inc.2025 Analyst Calls & High Return Stock Watch Alerts - newser.com
Is Astria Therapeutics Inc. stock overvalued by current metricsEarnings Overview Summary & Weekly Sector Rotation Insights - newser.com
Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors - Barron's
Astria Therapeutics (NASDAQ:ATXS) Hits New 1-Year HighHere's Why - MarketBeat
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Business Wire
Published on: 2025-10-31 05:48:56 - newser.com
Is Astria Therapeutics Inc. stock a contrarian buyQuarterly Portfolio Summary & Daily Entry Point Alerts - newser.com
Institutional scanner results for Astria Therapeutics Inc.2025 Top Gainers & Step-by-Step Trade Execution Guides - newser.com
Multi factor analysis applied to Astria Therapeutics Inc.Weekly Market Outlook & Accurate Technical Buy Alerts - newser.com
What MACD and RSI say about Astria Therapeutics Inc.Weekly Profit Summary & AI Driven Stock Price Forecasts - newser.com
Chart overlay techniques for tracking Astria Therapeutics Inc.Earnings Trend Report & Safe Capital Growth Trade Ideas - newser.com
Is Astria Therapeutics Inc. trending in predictive chart modelsMarket Rally & Free Safe Capital Growth Stock Tips - newser.com
Combining price and volume data for Astria Therapeutics Inc.Portfolio Value Summary & Low Drawdown Investment Ideas - newser.com
Can Astria Therapeutics Inc. stock maintain operating marginsJuly 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
Magnetar Financial LLC's Strategic Acquisition of Astria Therape - GuruFocus
What analysts say about Astria Therapeutics Inc stockInsider Trading Activity & Create Your Free Watchlist Instantly - earlytimes.in
Evaluating Astria Therapeutics Inc. with trendline analysisWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
Astria Therapeutics’ STAR-0310 Study: A Promising Step Forward - TipRanks
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):